Diagnosis & Disease Information

Imjudo Plus Imfinzi Approved for Unresectable Hepatocellular Carcinoma

The Food and Drug Administration (FDA) has approved Imjudo (tremelimumab-actl) in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma (HCC). Imjudo is a human monoclonal antibody that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The novel dose and schedule of the combination (the STRIDE regimen [Single Tremelimumab Regular Interval…